Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Alzinova initiates development of a stable cell line to prepare the monoclonal antibody ALZ-201 for Alzheimer's clinical trials | ||
By: PR Newswire Association LLC. - 24 May 2022 | Back to overview list |
|
STOCKHOLM, May 24, 2022 /PRNewswire/ -- Alzinova AB (publ) ("Alzinova" or the "Company") today announces the initiation of the next step in the preclinical development of its oligomer-specific monoclonal antibody, ALZ-201. The Company is developing ALZ-201 as a second product in its portfolio of Alzheimer's treatments, along with its vaccine candidate, ALZ-101, which is currently in Phase 1b clinical development. The Company has now initiated the development of a stable cell line to produce high and consistent levels of ALZ-201. In this process, the goal is to isolate single, viable, and high-producing cell clones to ensure compatibility with large-scale production of ALZ-201 in bioreactors. Alzinova has selected a collaboration partner to manage this work as a step in preparing the antibody for clinical trials. Unique oligomer specificity Anders Sandberg, Chief Scientific Officer at Alzinova, comments, "With its unique binding profile, ALZ-201 stands out for us as the only antibody specifically targeting toxic amyloid beta. Preventing oligomers' toxic effect on brain cells could translate into high efficacy and more favourable safety profiles, with "best-in-class" potential compared to other amyloid beta-targeting immunotherapies. By initiating this next step to develop a stable cell line to produce ALZ-201, we are furthering our commitment to utilise our unique technology to develop disease modifying therapies to help patients suffering from Alzheimer's disease." For more information, please contact: About ALZ-201 About Alzinova AB This information was brought to you by Cision http://news.cision.com The following files are available for download: |
||
|
||
Copyright 2022 PR Newswire Association LLC. | Back to overview list |